Minoxidil topical

Pronunciation

Class: Skin and Mucous Membrane Agents, Miscellaneous
ATC Class: C02DC01
VA Class: DE900
Chemical Name: 3-oxide 6-(1-piperidinyl)-2,4-pyrimidinediamine
Molecular Formula: C9H15N5O
CAS Number: 38304-91-5
Brands: Hair Regrowth, Rogaine, Theroxidil

Introduction

Hair stimulant; a piperidinopyrimidine-derivative vasodilator.5 19 20 37 43 44 73 4 9 14 15 20 40 43 56

Uses for Minoxidil

Androgenetic Alopecia

Stimulates regrowth of hair in men and women with androgenetic alopecia (male-pattern alopecia, hereditary alopecia, common male baldness).1 5 6 7 8 9 15 16 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 39 40 59 83 85

Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections

Recommended for use in men who have general thinning of hair at the vertex of the scalp 115 116 121 122 123 126 and in women who have general thinning of hair in frontoparietal areas.115 117 May be ineffective in men or women with more extensive hair loss.116 117 121 122 123 126

Not recommended for patients without a family history of hair loss or for those with hair loss associated with childbirth, or for those who have hair loss that occurs suddenly or for unknown reasons.116 117 121 122 123 126

Generally most effective in men <40 years of age,5 115 116 100 101 with <10 years duration of hair loss,6 23 39 100 101 115 116 <10 cm diameter of baldness, 5 6 23 39 100 101 115 116 and with large number of terminal or intermediate hairs before initiation of therapy.5 23 39 100 101

Alopecia Areata

Has been used to promote hair regrowth in males and females with alopecia areata, including alopecia totalis or universalis.9 44 45 46 47 48 49 50 51 52 53

Hair Transplantation

Has been used as an adjunct to hair transplantation; may promote better evolution of hair grafts by reducing postoperative shedding of hair and hastening the onset of postsheddng hair regrowth.64 65

Minoxidil Dosage and Administration

Administration

Topical Administration

Apply topically to the scalp as a 2 or 5% solution or as a 5% foam.1 116 117 121 122 123 126 a b c d

For dermatologic use only;1 116 117 121 122 123 126 avoid contact with eyes, mucous membranes, or sensitive or abraded skin areas.1 40 85 101 (See Dermatologic Effects under Cautions.) If contact with any of these areas occurs, flush area with large amounts of cool water.1 85 116 117 121 122 123

Apply to the scalp only; do not apply to other areas of the body because of risk of systemic adverse effects.116 117 121 122 123 126 (See Systemic Effects under Cautions.)

In men, apply 2 or 5% solution or 5% foam to total affected (balding and anticipated balding) areas of the scalp twice daily, usually in the morning and evening.1 5 6 7 8 9 15 16 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 39 40 59 83 101 116 117 121 122 123 126 c

In women, apply 2% solution to total affected areas of the scalp twice daily, usually in the morning and evening;117 d 5% solution and 5% foam should not be used in women.126 b c

Apply solution and foam to dry scalp.1 85 116 117 121 122 123 126 a b c d

To apply solution, use applicator provided by the manufacturer and apply evenly over total affected areas of the scalp.85 a b d

To apply foam, part hair into ≥1 rows to expose scalp.c Rinse hands with cold water and dry thoroughly to minimize foam melting on warm skin.c Hold container upside down and press nozzle to dispense ½ capful of foam onto fingers; apply foam to affected areas and gently massage into scalp.c

Wash hands thoroughly after application using fingertips.1 116 117 121 122 123 126 a b c d

Dosage

Adults

Androgenetic Alopecia
Treatment in Men
Topical

Apply 1 mL of 2 or 5% solution to affected areas of the scalp twice daily.1 5 6 7 8 9 15 16 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 39 40 59 83 101 116 117 121 122 123 126 a b

Apply ½ capful of 5% foam to affected areas of the scalp twice daily.c

≥4 months of use may be necessary before regrowth observed.1 5 6 7 67 101 116 117 121 122 123 126 a b c d Therapy must be continued indefinitely for maintenance of hair growth.1 6 7 9 24 40 67 83 100 101 109 115 116 121 122 123 126

Treatment in Women
Topical

Apply 1 mL of 2% solution to affected areas of the scalp twice daily.117 d

≥4 months of use may be necessary before regrowth observed.1 5 6 7 67 101 116 117 121 122 123 126 a b c d Therapy must be continued indefinitely for maintenance of hair growth.1 6 7 9 24 40 67 83 100 101 109 115 116 121 122 123 126

Alopecia Areata
Topical

Apply 1 mL of 5% solution to affected areas of the scalp twice daily.45 46 49 52 53 100 101

Prescribing Limits

Adults

Androgenetic Alopecia
Treatment in Men
Topical

Maximum 2 mL of 2 or 5% solution daily.1 116 117 121 122 123 126 a b d

Maximum ½ capful of 5% foam per application.c

Treatment in Women
Topical

Maximum 2 mL of 2% solution daily.1 116 117 121 122 123 126 a d

Special Populations

No special population dosage recommendations at this time.a b c d

Cautions for Minoxidil

Contraindications

  • Known hypersensitivity to minoxidil or any ingredient in the formulation.1

Warnings/Precautions

General Precautions

Dermatologic Effects

Possible adverse local dermatologic effects (e.g., pruritus, dryness, scaling/flaking, local irritation or burning);1 5 8 9 15 16 22 23 26 27 29 30 32 40 46 56 83 85 96 may occur more frequently with the 5 than the 2% topical solution126 and may result from alcohol contained in formulation1 85 and the wearing of a wig or hairpiece.53 Local irritation usually is mild1 5 9 15 16 26 29 38 39 46 51 53 56 83 85 96 and rarely requires discontinuance of therapy.46 51 56

If irritation occurs, flush area with large amounts of cool water; contact clinician if irritation persists.1 85 116 117 121 122 123

Increased hair growth outside area of drug application (e.g., face, beard, eyebrows, ear, arm) reported; possibly due to inadvertent transfer of drug solution.1 5 22 32 46 50 51 52 83

Systemic Effects

Potential systemic adverse effects (e.g., weight gain, edema, tachycardia, hypotension),1 9 22 32 40 86 93 100 110 111 especially in individuals with propensity for greater percutaneous absorption or with increased sensitivity to the drug.1 9 93 101 Excessive doses, local abrasion or inflammation, or severe sunburn also may increase risk of systemic effects.1 101 116 117 121 122 123 a b d

Use not recommended on inflamed, erythematous, infected, irritated, or painful scalp.116 117 121 122 123 a b c d

Exposure to UV Light

Severe UV light-induced skin injury (e.g., severe sunburn) may enhance percutaneous absorption and increase risk of systemic effects.1 101 (See Systemic Effects under Cautions.)

Specific Populations

Pregnancy

Category C.e

Lactation

Distributed into milk after oral administration;72 115 however, not known whether topical minoxidil is distributed into milk.d AAP classifies minoxidil as compatible with breast-feeding.e

Pediatric Use

Safety and efficacy not established in children <18 years of age.1

Women

Prior to initiating therapy for androgenetic alopecia, consider possibility of an underlying endocrine abnormality (e.g., polycystic ovary [Stein-Leventhal] syndrome, Cushing’s syndrome, androgen-secreting tumors, hypothyroidism).9 84 100 101

Severe, diffuse hypertrichosis involving the face and limbs reported in women after 2–3 months of therapy with 5% solution for treatment of androgenetic alopecia; resolved within 4–5 months following discontinuance of therapy.132

Common Adverse Effects

Pruritus, 1 5 8 9 15 16 22 23 26 27 29 30 32 40 46 56 83 85 96 dryness, 5 22 40 83 scaling/flaking, 1 5 9 26 46 83 local irritation or burning.1 5 9 15 16 26 29 38 39 46 51 53 56 83 85 96

Interactions for Minoxidil

Topical Preparations

Possible pharmacokinetic interaction (increased percutaneous absorption of minoxidil).101 129 130 Safety and efficacy of combined therapy with other topical drugs not established.131 Concomitant use with other topical drugs on the scalp is not recommended.a b c d

Specific Drugs

Drug

Interaction

Comments

Hypotensive agents (guanethidine)

Possible increased risk of orthostatic hypotension if systemic absorption of minoxidil occurs1

Use concomitantly with caution1

Tretinoin, topical

Potential increased percutaneous absorption of minoxidil101 129 130

Safety and efficacy of combined use requires further evaluation131

Minoxidil Pharmacokinetics

Absorption

Bioavailability

Minimally absorbed following topical application to intact scalp;1 15 16 43 61 1.4% of a 2% topical solution may be absorbed.70

Onset

Onset of hair regrowth is variable; however, 2 or ≥4 months usually required before evidence of regrowth is observed following topical administration with 2 or 5% topical solutions, respectively.1 23 25 27 30 34 36 59 101 116 117 121 122 123 126

Distribution

Extent

Not fully determined following topical administration;100 101 however, intact stratum corneum may serve as a barrier that inhibits substantial diffusion of topically applied minoxidil into systemic circulation.68 71 101

Not known whether topical minoxidil crosses the placenta or is distributed into milk.1 72 e

Elimination

Metabolism

Not fully determined following topical administration;1 however, appears to be converted in the hair follicle to an active metabolite, minoxidil sulfate, by minoxidil sulfotransferase.17

Elimination Route

Excreted principally in urine.61

Stability

Storage

Topical

Solution

20–25°C.126 132 Keep away from heat and flame.a b d

Foam

20–25°C.c Keep away from heat and flame; do not puncture or incinerate container.c

Actions

  • Exact mechanism of action not fully elucidated; however, appears to act at the level of the hair follicle,4 5 6 7 9 10 14 15 16 17 18 19 20 31 62 81 possibly directly stimulating hair follicle epithelial growth.4 6 9 10 14 15 17 18 19 20 81 100

  • May induce follicle hypertrophy and a return to more normal hair follicle diameter and depth in existing small follicles (i.e., regrowth) rather than stimulation of new follicle formation.4 5 6 7 9 17 19 20 59

  • Appears to prolong the anagen phase of the hair follicle, and accelerate the cyclic turnover of vellus hair follicles, enabling these follicles to produce thick, terminal hair4 6 9 19 20 106

  • May directly induce proliferation of hair epithelial cells near the base of the hair follicle and increase incorporation of cysteine and glycine into the follicle;14 cysteine residues cross-link to form cystine, which provides strength to the hair shaft.59

Advice to Patients

  • Product is flammable; importance of keeping product and area of application away from open flame and heat.a b c d

  • Importance of using only as directed, only for the indicated types of hair loss, and for at least 2–4 months in order to see results; continuous use required to maintain hair regrowth.a b c d (See Topical Administration under Dosage and Administration.)

  • Importance of applying only to healthy, normal scalp and not using topical minoxidil if scalp is inflamed, erythematous, infected, irritated, or painful.116 117 121 122 123 Importance of avoiding contact with the eyes.a b c d

  • Importance of washing hands after application.a b c d

  • Importance of women using only 2% solution; 5% solution and 5% foam should not be used in women.a b c d

  • Importance of reporting any local or systemic adverse reactions, especially chest pain, tachycardia, dizziness, unexplained weight gain, or peripheral edema, to a clinician.a b c d

  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as concomitant illnesses.a b c d

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a b c d

  • Importance of informing patients of other important precautionary information.a b c d (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Minoxidil

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Topical

Solution

2%*

Hair Regrowth (with alcohol 60% and propylene glycol)

Eckerd, Rite Aid

Rogaine Hair Regrowth Treatment for Men (with alcohol 60% and propylene glycol)

Pfizer

Rogaine Hair Regrowth Treatment for Women (with alcohol 60% and propylene glycol)

Pfizer

5%*

Rogaine for Men Extra Strength (with alcohol 30% and propylene glycol)

Pfizer

Theroxidil (with alcohol 30% and propylene glycol)

Harmony

Foam

5%*

Rogaine Hair Regrowth Treatment for Men (with alcohol SD 40-B, butane, butylated hydroxytoluene, isobutane, and propane)

Pfizer

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Minoxidil For Men 5% Solution (ACTAVIS MID ATLANTIC): 60/$23.99 or 180/$59.97

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions November 1, 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. The Upjohn Company. Rogaine (minoxidil topical solution) prescribing information. Kalamazoo, MI; 1990 Feb.

2. The Upjohn Company. Rogaine (minoxidil topical solution) product information. Kalamazoo, MI; 1988 Aug.

3. Dawber RPR. Aetiology and pathophysiology of hair loss. Dermatologica. 1987; 175(Suppl 2):23-8.

4. Headington JT. Hair follicle biology and topical minoxidil: possible mechanisms of action. Dermatologica. 1987; 175(Suppl 2):19-22. [PubMed 3319729]

5. Katz HI. Topical minoxidil: review of efficacy and safety. Cutis. 1989; 43:94-8. [PubMed 2644080]

6. Voorhees JJ. Editor’s summary. Dermatologica. 1987; 175(Suppl 2):54-6.

7. Katz HI. Topical minoxidil: review of efficacy. Clin Dermatol. 1988; 6:195-9. [PubMed 3063371]

8. Shupack JL, Kassimir JJ, Thirumoorthy T et al. Dose-response study of topical minoxidil in male pattern alopecia. J Am Acad Dermatol. 1987; 16:673-6. [PubMed 3549801]

9. Clissold SP, Heel RC. Topical minoxidil: preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs. 1987; 33:107-22. [IDIS 228948] [PubMed 3552591]

10. Fiedler-Weiss VC. Potential mechanisms of minoxidil-induced hair growth in alopecia areata. J Am Acad Dermatol. 1987; 16:653-6. [PubMed 3558910]

11. Bunker CB, Dowd PM. Topical minoxidil, scalp hair, and vasodilatation. Lancet. 1987; 1:1266.

12. Bunker CB, Dowd PM. Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia. Br J Dermatol. 1987; 117:668-9. [IDIS 237238] [PubMed 3689690]

13. Fiedler-Weiss VC, Buys CM. Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation. Br J Dermatol. 1987; 117:759- 63. [PubMed 3501310]

14. Buhl AE, Waldon DJ, Kawabe TT et al. Minoxidil stimulates mouse vibrissae follicles in organ culture. J Invest Dermatol. 1989; 92:315-20. [PubMed 2465357]

15. Fiedler VC. Minoxidil: clinical and basic research in perspective. Semin Dermatol. 1987; 6:101- 7.

16. Fiedler-Weiss VC. Minoxidil. Dermatol Clin. 1987; 5:627-35. [PubMed 3301118]

17. Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J Am Acad Dermatol. 1987; 16:657-68. [PubMed 3558911]

18. Fiedler VC, Buys CM. Immunohistochemical characterization of the cellular infiltrate in severe alopecia areata before and after minoxidil treatment. Dermatologica. 1987; 175(Suppl 2):29-35. [PubMed 2961630]

19. Headington JT, Novak E. Clinical and histologic studies of male pattern baldness treated with topical minoxidil. Curr Ther Res Clin Exp. 1984; 36:1098-106.

20. Uno H, Cappas A, Schlagel C. Cyclic dynamics of hair follicles and the effect of minoxidil on the bald scalps of stumptailed macaques. Am J Dermatopathol. 1985; 7:283-97. [PubMed 4051135]

21. Eller MG, Szpunar GJ, Della-Coletta AA. Absorption of minoxidil after topical application: effect of frequency and site of application. Clin Pharmacol Ther. 1989; 45:396-402. [IDIS 253526] [PubMed 2702797]

22. Olsen EA, Weiner MS, Delong ER et al. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol. 1985; 13:185-92. [PubMed 3900155]

23. De Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985; 121:197-202. [IDIS 196318] [PubMed 3883902]

24. Tosti A. Topical minoxidil useful in 18% of patients with androgenetic alopecia: a study of 430 cases. Dermatologica. 1986; 173:136-8. [PubMed 3770260]

25. Storer JS, Brzuskiewicz J, Floyd H et al. Review: topical minoxidil for male pattern baldness. Am J Med Sci. 1986; 291:328-33. [IDIS 215989] [PubMed 3518451]

26. Civatte J, Laux B, Simpson NB et al. 2% topical minoxidil solution in androgenetic baldness: preliminary European results. Dermatologica. 1987; 175(Suppl 2):42-9. [PubMed 3319731]

27. Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol. 1987; 16:677-85. [PubMed 3549802]

28. Kreindler TG. Topical minoxidil in early androgenetic alopecia. J Am Acad Dermatol. 1987; 16:718-24. [PubMed 3549807]

29. Roberts JL. Androgenetic alopecia: treatment results with topical minoxidil. J Am Acad Dermatol. 1987; 16:705-10. [PubMed 3549805]

30. Savin RC. Use of topical minoxidil in the treatment of male pattern baldness. J Am Acad Dermatol. 1987; 16:696-704. [PubMed 3549804]

31. Katz HI, Hien NT, Prawer SE et al. Long-term efficacy of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1987; 16:711-8. [PubMed 3549806]

32. Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol. 1987; 16:688-95. [PubMed 3549803]

33. Olsen EA, DeLong ER, Weiner MS. Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1986; 15:30-7. [PubMed 3722507]

34. De Villez RL. Androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1987; 16:669-72. [PubMed 3549800]

35. De Villez RL. Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. Dermatologica. 1987; 175(Suppl 2):50-3.

36. Koperski JA, Orenberg EK, Wilkinson DI. Topical minoxidil therapy for androgenetic alopecia. Arch Dermatol. 1987; 123:1483-7. [IDIS 235936] [PubMed 3314717]

37. Vanderveen EE, Ellis CN, Kang S et al. Topical minoxidil for hair regrowth. J Am Acad Dermatol. 1984; 11:416-21. [PubMed 6384289]

38. Weiss VC, West DP. Topical minoxidil therapy and hair regrowth. Arch Dermatol. 1985; 121:191-2. [IDIS 196316] [PubMed 3977331]

39. Rumsfield JA, West DP, Fiedler-Weiss VC. Topical minoxidil therapy for hair regrowth. Clin Pharm. 1987; 6:386-92. [IDIS 229037] [PubMed 3311578]

40. de Groot AC, Nater JP, Herxheimer A. Minoxidil: hope for the bald? Lancet. 1987; 1:1019-21. Editorial.

41. Mitchell AD, De Villez R. Minoxidil for male- pattern baldness. Lancet. 1987; 1:1436. [PubMed 2884528]

42. de Groot AC, Nater JP, Herxheimer A. Minoxidil for male-pattern baldness. Lancet. 1987; 2:563. [PubMed 2887848]

43. Novak E, Franz TJ, Headington JT et al. Topically applied minoxidil in baldness. Int J Dermatol. 1985; 24:82-7. [PubMed 3886571]

44. Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. BMJ. 1983; 287:1015-7. [IDIS 177632] [PubMed 6412929]

45. Weiss VC, West DP, Fu TS et al. Alopecia areata treated with topical minoxidil. Arch Dermatol. 1984; 120:457-63. [IDIS 185288] [PubMed 6703751]

46. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987; 16:730-6. [PubMed 3549809]

47. King CM, Harrop B, Dave VK. Topical minoxidil in the treatment of alopecia areata. BMJ. 1983; 287:1380. [IDIS 178404] [PubMed 6416428]

48. Maitland JM, Aldridge RD, Main RA et al. Topical minoxidil in the treatment of alopecia areata. BMJ. 1984; 288:794. [IDIS 183293] [PubMed 6423083]

49. Fiedler-Weiss VC, West DP, Buys CM et al. Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol. 1986; 122:180-2. [IDIS 211658] [PubMed 3947124]

50. White SI, Friedmann PS. Topical minoxidil lacks efficacy in alopecia areata. Arch Dermatol. 1985; 121:591. [IDIS 199275] [PubMed 3994404]

51. Price VH. Topical minoxidil in extensive alopecia areata, including 3-year follow-up. Dermatologica. 1987; 175(Suppl 2):36-41. [PubMed 3691913]

52. Price VH. Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. J Am Acad Dermatol. 1987; 16:737-44. [PubMed 3549810]

53. Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol. 1987; 16:745-8. [PubMed 3549811]

54. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann NY Acad Sci. 1951; 53:708- 28. [PubMed 14819896]

55. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975; 68:1359-65. [PubMed 1188424]

56. Roenigk HH Jr, Pepper E, Kuruvilla S. Topical minoxidil therapy for hereditary male pattern alopecia. Cutis. 1987; 39:337-42. [PubMed 3556042]

57. Paraskevas D, Rekkas D, Choulis N et al. In vitro release of minoxidil from topical formulations. Arch Dermatol. 1987; 123:1433-4. [PubMed 3674904]

58. Anon. Unapproved use of minoxidil. FDA Drug Bull. 1985; 15:38.

59. Kvedar JC, Baden HP. Topical minoxidil in the treatment of male pattern alopecia. Pharmacotherapy. 1987; 7:191-7. [IDIS 391046] [PubMed 3328164]

60. Ebling FJ. Biology of hair follicles. In: Fitzpatrick TB, Eisen AZ, Wolff K et al, eds. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill Book Company; 1987:213-9.

61. Franz TJ. Percutaneous absorption of minoxidil in man. Arch Dermatol. 1985; 121:203-6. [IDIS 196319] [PubMed 3977334]

62. Wester RC, Maibach HI, Guy RH et al. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol. 1984; 82:515-7. [IDIS 185351] [PubMed 6239893]

63. Chiang CM, Flynn GL, Weiner ND et al. Bioavailability assessment of topical delivery systems: in vitro delivery of minoxidil from prototypical semi- solid formulations. Int J Pharm. 1989; 49:109-14.

64. Bouhanna P. Topical minoxidil used before and after hair transplantation. J Dermatol Surg Oncol. 1989; 15:50-3. [PubMed 2910964]

65. Kassimir JJ. Use of topical minoxidil as a possible adjunct to hair transplant surgery. J Am Acad Dermatol. 1987; 16:685-7. [PubMed 3558912]

66. Szpunar GJ, Dalm EP, Albert KS. The effect of using shaved versus bald scalps on the bioavailability of topically applied minoxidil 2% solution. Pharm Res. 1986; 3(Suppl):114S.

67. Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. 1987; 17:97-101. [PubMed 3301926]

68. Fiedler-Weiss VC, Rumsfield J, Buys CM et al. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol. 1987; 123:1488-90. [IDIS 235937] [PubMed 3674909]

69. Eller MG, Szpunar GJ, Della-Coletta AA et al. Systemic absorption of minoxidil after topical application: effect of minoxidil concentration. Clin Pharmacol Ther. 1988; 43:137.

70. Szpunar GJ, Dalm EP, Albert KS. The bioavailability of 2% and 3% minoxidil topical solutions relative to a 2.5 mg oral minoxidil tablet (Loniten-Upjohn). Pharm Res. 1986; 3(Suppl):114S.

71. Stehle RG, Ho NFH, Grady RK et al. In vitro percutaneous absorption of minoxidil and characterization of metabolic properties of hairless mouse skin. Pharm Res. 1986; 3(Suppl):72S.

72. Valdivieso A, Valdes G, Spiro TE et al. Minoxidil in breast milk. Ann Intern Med. 1985; 102:135. [IDIS 194820] [PubMed 3966734]

73. The Upjohn Company. Loniten (minoxidil oral tablets) prescribing information. Kalamazoo, MI; 1986 Mar.

74. Schop RN, Goldberg MT. Nongenotoxicity of minoxidil in murine hair follicles as determined by the nuclear aberration assay. Toxicol Appl Pharmacol. 1988; 92:150-4. [PubMed 3341023]

75. Kubilus J, Kvedar JC, Baden HP. Effect of minoxidil on pre- and postconfluent keratinocytes. J Am Acad Dermatol. 1987; 16:648-52. [PubMed 2435772]

76. The United States Pharmacopeia, 21st rev. and The national formulary, 16th ed. Suppl 7. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1988:2902.

77. Muller SA. Alopecia: syndromes of genetic significance. J Invest Dermatol. 1973; 60:475-92. [PubMed 4581946]

78. Tromovitch TA, Glogau RG, Stegman SJ. Medical treatment of male pattern alopecia (androgenic alopecia). Head Neck Surg. 1985; 7:336-9. [PubMed 3988537]

79. Adachi K. The metabolism and control mechanism of human hair follicles. Curr Probl Dermatol. 1973; 5:37-78. [PubMed 4362370]

80. Fiedler-Weiss VC, Johnson GA, Buys CM et al. Minoxidil sulfate and sulfotransferase activity in alopecia areata. Clin Res. 1987; 35:682A.

81. Cohen RL, Alves MEAF, Weiss VC et al. Direct effects of minoxidil on epidermal cells in culture. J Invest Dermatol. 1984; 82:90-3. [PubMed 6197493]

82. Fiedler-Weiss VC, Buys CM. Alopecia areata and control lymphocyte blastogenesis suppressed by in vitro minoxidil. J Invest Dermatol. 1986; 87:139.

83. Anon. Topical minoxidil for baldness. Med Lett Drugs Ther. 1987; 29:87-8. [PubMed 3306300]

84. Dawber RPR. Alopecia and hirsutism. Clin Exp Dermatol. 1982; 7:177-82. [PubMed 7083623]

85. The Upjohn Company. Minoxidil topical solution (Rogaine): information for the patient. Kalamazoo, MI; 1988 Aug.

86. Leenen FHH, Smith DL, Unger WP. Topical minoxidil: cardiac effects in bald man. Br J Clin Pharmacol. 1988; 26:481-5. [IDIS 247112] [PubMed 3191000]

87. Baral J. Scalp comedones after topical minoxidil. J Am Acad Dermatol. 1985; 13:1051. [PubMed 2934443]

88. Olsen EA. Scalp comedones after topical minoxidil. J Am Acad Dermatol. 1985 13:1051-2. Reply.

89. van der Willigen AH, Dutree-Meulenberg RO, Stolz E et al. Topical minoxidil sensitization in androgenic alopecia. Contact Dermatitis. 1987; 17:44- 5. [PubMed 2958212]

90. Tosti A, Bardazzi F, De Padova MP et al. Contact dermatitis to minoxidil. Contact Dermatitis. 1985; 13:275-6. [PubMed 4085233]

91. Degreef H, Hendrickx I, Dooms-Goossens A. Allergic contact dermatitis to minoxidil. Contact Dermatitis. 1985; 13:194-5. [PubMed 2932293]

92. Castillo G, Moshell AN, Jorgensen H et al. Contact sensitization to topically applied minoxidil solution: possible mechanism of action. Clin Res. 1985; 33:629A.

93. Yates VM, King CM, Harrop B. Topical minoxidil in the treatment of alopecia areata. BMJ. 1984; 288:1087. [PubMed 6423205]

94. Ranchoff RE, Bergfeld WF. Topical minoxidil reduces blood pressure. J Am Acad Dermatol. 1985; 12:586-7. [PubMed 3989020]

95. Feinstein RP. The effect of topical minoxidil on blood pressure. J Am Acad Dermatol. 1985; 13:673- 4. [PubMed 3908507]

96. Pestana A, Olsen EA, Delong ER et al. Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness. J Am Acad Dermatol. 1987; 16(5 Pt 1):971-6. [PubMed 3294945]

97. Herring BD. Unravelling the pathophysiology of male pattern baldness. J Natl Med Assoc. 1985; 77:142,145. [PubMed 3981649]

98. Mitchell AJ, Krull EA. Alopecia areata: pathogenesis and treatment. J Am Acad Dermatol. 1984; 11:763-75. [PubMed 6210311]

99. Parker LN, Lifrak ET, Odell WD. Lack of a gonadal or adrenal androgenic mechanism for the hypertrichosis produced by diazoxide, phenytoin and minoxidil. Biochem Pharmacol. 1982; 31:90-3.

100. Reviewers’ comments (personal observations); 1989 Jul.

101. Cohon MS (The Upjohn Company, Kalamazoo, MI): Personal communication; 1989 July 13.

102. Linas SL, Nies AS. Minoxidil. Ann Intern Med. 1981; 94:61-5. [IDIS 126669] [PubMed 6108737]

103. Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol. 1979; 101:593-5. [IDIS 107954] [PubMed 518830]

104. Mehta PK, Mamdani B, Shansky RM et al. Severe hypertension: treatment with minoxidil. JAMA. 1975; 233:249-52. [PubMed 1173832]

105. Baden HP, Kubilus J. Effect of minoxidil on cultured keratinocytes. J Invest Dermatol. 1983; 81:558-60. [PubMed 6196423]

106. Abell E, Cary MM. The pathologic effect of minoxidil in male pattern alopecia. J Invest Dermatol. 1986; 86:459.

107. De Boer EM, Bezemer PD, Bruynzeel DP et al. Does topical minoxidil increase skin blood flow? Acta Derm Venereol (Stockh). 1988; 68:271-4.

108. Rietschel RL, Robertson DB. Duration of minoxidil therapy to yield maximum benefit. Arch Dermatol. 1988; 124:1569. [IDIS 252837] [PubMed 3421734]

109. Olsen EA, Weiner MS, Amara IA et al. Five year follow-up of men with androgenetic alopecia treated with topical minoxidil. (unpublished observations) J Am Acad Dermatol. 1990; 22:643-6.

110. Spindler JR. Deaths occurring during clinical studies of topical minoxidil. J Am Acad Dermatol. 1987; 16:725-9. [PubMed 3549808]

111. Baral J. Minoxidil and sudden death. J Am Acad Dermatol. 1985; 13:297-8. [PubMed 4044954]

112. Vanderveen EE. Minoxidil and sudden death. J Am Acad Dermatol. 1985; 13:298-9.

113. Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. 1986; 15(4 Part 2):880-3,890-3. [PubMed 3771854]

114. Whiting DA. The treatment of alopecia areata. Cutis. 1987; 40:247-50. [PubMed 3308336]

115. Pharmacia & Upjohn. Rogaine (minoxidil) topical solution prescribing information. In: Physicians’ desk reference. 50th ed. Montvale, NJ: Medical Economics Company. 1996; 2637- 41.

116. Pharmacia & Upjohn. Rogaine Hair Regrowth Treatment for Men (minoxidil) topical solution patient information. Kalamazoo, MI; undated (816-693-000).

117. Pharmacia & Upjohn. Rogaine Hair Regrowth Treatment for Women (minoxidil) topical solution patient information. Kalamazoo, MI; undated (816-701-000).

118. DeVillez RL, Jacobs JP, Szpunar CA et al. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol. 1994; 130:303-7. [IDIS 327148] [PubMed 8129407]

119. Jacobs JP, Szpunar CA, Warner ML. Use of topical minoxidil therapy for androgenetic alopecia in women. Int J Dermatol. 1993; 32:758-62. [PubMed 8225725]

120. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977; 97:247-54. [PubMed 921894]

121. Copley Pharmaceutical Inc. Minoxidil topical solution 2% patient information. Canton, MA; undated (LEA500702).

122. Bausch & Lomb Pharmaceuticals, Inc. Minoxidil topical solution 2% patient information. Tampa, FL; 1996 May.

123. Barre-National Inc. Minoxidil topical solution 2% patient information. Baltimore, MD; 1996 Mar.

124. Whiting DA, Jacobson C. Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol. 1992; 31:800-4. [PubMed 1428436]

125. Olsen EA. Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis. 1991; 48:243-8. [PubMed 1935254]

126. Pharmacia & Upjohn Consumer Healthcare. Rogaine Extra Strength for Men Hair Regrowth Treatment (minoxidil) topical solution patient information. Kalamazoo, MI; undated (817-069-000).

127. Pharmacia & Upjohn consumer Healthcare, Kalamazoo, MI: Personal communication.

128. Tata S, Flynn GL, Weiner ND. Penetration of minoxidil from ethanol/propylene glycol solutions: effect of application volume and occlusion. J Pharm Sci. 1995; 84:688-91. [PubMed 7562405]

129. Walsh DS, Dunn CL, James WD et al. Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride. Arch Dermatol. 1995; 131:1373-5. [IDIS 357195] [PubMed 7492124]

130. Ferry JJ, Forbes KK, Vanderlugt JT et al. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clin Pharmacol Ther. 1990; 47:439-46. [IDIS 267300] [PubMed 2328551]

131. Rand S. Hair growth therapy(ies) for androgenetic alopecia. Arch Dermatol. 1996; 132:714-5. [IDIS 368733] [PubMed 8651731]

132. Pharmacia & Upjohn. Rogaine For Women Hair Regrowth Treatment (minoxidil 2%) Topical Solution product information. In: Physician's desk reference for nonprescription drugs. 21st ed. Montvale, NJ; Medical Economics Company Inc; 2000:711-2.

a. Pfizer. Rogaine For Men Hair Regrowth Treatment (minoxidil 2%) Topical Solution product information. 2006.www.rogaine.com. accessed March 30, 2007.

b. Pfizer. Rogaine For Men Hair Regrowth Treatment (minoxidil 5%) Topical Solution product information. 2006. www.rogaine.com. accessed March 30, 2007.

c. Pfizer. Rogaine For Men Hair Regrowth Treatment (minoxidil 5%) Topical Foam product information. 2006. www.rogaine.com. accessed March 30, 2007.

d. Pfizer. Rogaine For Women Hair Regrowth Treatment (minoxidil 2%) Topical Solution product information. 2006. www.rogaine.com. accessed March 30, 2007.

e. Minoxidil. In: Briggs GG, Freeman RK, Yaffe SJ. Drug in pregnancy and lactation: a reference guide to fetal and neonatal risk. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:1087-90.

Hide
(web1)